IRIS
PITINI, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.474
EU - Europa 3.962
AS - Asia 2.329
SA - Sud America 940
AF - Africa 65
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 11.778
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.415
RU - Federazione Russa 1.293
SG - Singapore 1.019
BR - Brasile 841
IE - Irlanda 711
SE - Svezia 694
CN - Cina 692
UA - Ucraina 343
HK - Hong Kong 303
DE - Germania 285
GB - Regno Unito 154
FI - Finlandia 150
IT - Italia 130
VN - Vietnam 95
FR - Francia 45
BE - Belgio 39
IN - India 36
AR - Argentina 35
BD - Bangladesh 25
MX - Messico 24
PL - Polonia 23
TR - Turchia 23
ZA - Sudafrica 23
CA - Canada 18
CZ - Repubblica Ceca 18
EC - Ecuador 18
IQ - Iraq 18
JP - Giappone 17
AT - Austria 16
NL - Olanda 16
UZ - Uzbekistan 13
MA - Marocco 12
VE - Venezuela 12
AZ - Azerbaigian 11
CO - Colombia 9
ES - Italia 9
TN - Tunisia 9
PK - Pakistan 8
PY - Paraguay 8
IL - Israele 7
IR - Iran 7
KE - Kenya 7
PE - Perù 7
AE - Emirati Arabi Uniti 6
ID - Indonesia 6
LT - Lituania 6
OM - Oman 5
AM - Armenia 4
BO - Bolivia 4
CI - Costa d'Avorio 4
DO - Repubblica Dominicana 4
JO - Giordania 4
NO - Norvegia 4
PA - Panama 4
AL - Albania 3
BN - Brunei Darussalam 3
BY - Bielorussia 3
CL - Cile 3
EG - Egitto 3
LV - Lettonia 3
NP - Nepal 3
PS - Palestinian Territory 3
QA - Qatar 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
EE - Estonia 2
EU - Europa 2
GE - Georgia 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
NZ - Nuova Zelanda 2
PH - Filippine 2
RO - Romania 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BG - Bulgaria 1
CG - Congo 1
CH - Svizzera 1
GA - Gabon 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
ML - Mali 1
MY - Malesia 1
Totale 11.772
Salva come PNG Salva come JPEG
Città #
Dublin 711
Jacksonville 651
Moscow 620
Chandler 567
Singapore 530
Ashburn 508
Dallas 448
Nyköping 358
Beijing 302
Hong Kong 301
Ann Arbor 156
Princeton 123
Cambridge 119
Los Angeles 111
Des Moines 100
Dearborn 93
The Dalles 88
Medford 86
Boardman 70
New York 66
Lancaster 61
Woodbridge 60
Munich 59
Messina 55
São Paulo 55
Buffalo 53
Wilmington 39
Tianjin 38
Brussels 37
Jinan 35
Ho Chi Minh City 33
Redondo Beach 28
Rio de Janeiro 26
Shenyang 26
Houston 25
San Mateo 22
Turku 22
Hanoi 21
Seattle 21
Chicago 20
Warsaw 20
Belo Horizonte 19
Santa Clara 18
Council Bluffs 17
Ningbo 17
Brno 16
Düsseldorf 16
Haikou 16
Nanjing 16
Tokyo 16
Zhengzhou 15
Brasília 14
Denver 14
Nanchang 14
Vienna 14
Auburn Hills 13
Stockholm 13
Taizhou 13
Atlanta 12
Goiânia 12
Hangzhou 12
Hebei 12
Baku 11
Brooklyn 11
Curitiba 11
Frankfurt am Main 11
Guangzhou 11
Johannesburg 11
Salvador 11
Tashkent 11
Boston 10
Campinas 10
Chennai 10
Porto Alegre 10
Baghdad 9
Phoenix 9
Quito 9
Ribeirão Preto 9
San Francisco 9
Buenos Aires 8
Hyderabad 8
Manaus 8
Montreal 8
Pune 8
Santo André 8
Bologna 7
Bremen 7
Helsinki 7
Joinville 7
Nairobi 7
Norwalk 7
Recife 7
San Jose 7
Shanghai 7
São José dos Campos 7
Washington 7
Amsterdam 6
Betim 6
Cape Town 6
Catania 6
Totale 7.395
Salva come PNG Salva come JPEG
Nome #
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 179
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options 171
Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience 158
An accessory spleen wrongly recognised as relapse by positron emission tomography 156
Emerging markers of cachexia predict survival in cancer patients. 153
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. 153
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 151
An acute-leukaemia-like picture due to breast carcinoma cells. 149
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 148
CLINICAL ACTIVITY OF BORTEZOMIB IN RELAPSED OR REFRACTORY GASTRIC MARGINAL ZONE B-CELL LYMPHOMA OF MALT TYPE 144
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report 142
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas 138
AMIFOSTINE IN CONJUCTION WITH H.D. VP16 AND G-CSF ENABLE PBSC COLLECTION IN MULTIPLE MYELOMA PATIENTS WHO FAILED CTX INDUCED MOBILIZATION 137
Trattamento endoscopico scleroterapico nelle neoplasie sanguinanti del tratto digestivo. 136
Amplification and overexpression of the PSMB5 gene contribute to Bortezomib resistance in re-treatment of patients with Multiple Myeloma 136
Effect of treatment with amifostine in patients with myelodisplastic syndromes on clinical outcome and apoptosis in bone marrow 136
Amifostine in conjuction with G-CSF enhances chemoterapy mobilization of peripheral blood progenitor cell 133
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 133
Beta=interferon in the treatment of 14 patie nts with advanced colorectal carcinoma. J Exp Pathol. 1987 Summer;3(4):603-5. No abstract available. PMID: 3454807 [PubMed - indexed for MEDLINE] 132
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 130
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST 129
A sequential chemoimmunotherapy protocol can obtain a high proportion of molecular remission in chronic lymphocytic leukaemia 128
ANCHE IN VIVO IL PAMIDRONATO E' UN INDUTTORE DELLA APOPTOSI NELLE PLASMACELLULE MIELOMATOSE 127
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 125
AN UNUSUAL PRESENTATION OF SCHISTOSOMIASIS 123
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 122
Endobronchial electrocautery for the dehydration of lung cancer. 122
CIRCULATING PLASMA CELLS IN MULTIPLE MYELOMA: CORRELATION WITH DISEASE STAGE 121
Thyroid function, autoimmunity and nodules in hematological malignancies 121
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation 120
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? 120
Fatal delayed diagnosis in a patient with falciparum malaria 120
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms 118
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 116
Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? 114
Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes 114
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 113
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 112
Myelodysplastic syndrome/acute myelogenous leukaemia after adjuvant chemotherapy with pyrimidine anti-metabolites in three patients 111
Salvage therapy for primary central nervous system lymphoma with Y-90-Ibritumomab and Temozolomide 110
IMATINIB-INDUCED APOPTOSIS IN EOSINOPHILS OF PATIENTS WITH A HYPEREOSINOPHILIC SYNDROME PREDICTS RESPONSE TO TREATMENT 107
DASATINIB INDUCES A RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA 106
Circulating plasma cells in Multiple Myeloma: correlation with disease stage 105
Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma. 105
Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report 104
Use of bisphosphonates in oncology 104
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 103
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? 102
Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma 101
Acute neurotoxicity as a serious adverse event related to rasburicase in a non-Hodgkin's lymphoma patient 101
Temozolomide-induced shrinkage of a pituitary carcinoma. 101
Resistance to PGE(2) inhibition of PWM-stimulated lymphocytes from neoplastic patients 100
ERLOTINIB IN A PATIENT WITH ACUTE MYELOGENOUS LEUKEMIA AND CONCOMITANT NON-SMALL-CELL LUNG CANCER 100
Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: A surrogate marker of response? 100
How cells respond to interferons. 100
Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF 100
null 99
MYELODYSPLASTIC SYNDROMES DEVELOPING DURING IMATINIB THERAPY FOR GIST 98
OUR EXPERIENCE ON THE EFFECTS OF TAMOXIFEN ON BLOOD COAGULATION IN PATIENTS OPERATED FOR BREAST CANCER Folia Oncologica vol.XIV-n.2-3 (Aprile-Settembre)-1991 96
IMMUNOCHEMOTHERAPY WITH RITUXIMAB AND TEMOZOLOMIDE FOR CENTRAL NERVOUS SYSTEM LYMPHOMAS 95
MORPHOLOGICAL, PHENOTYPIC AND KARYOTYPIC CHARACTERIZATION OF A NOVEL NATURAL-KILLER-CELL TARGET - EVIDENCE OF INVOLVEMENT OF MHC CLASS-I MOLECULES IN NK CELL RECOGNITION 95
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 94
Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease 94
ADVERSE PROGNOSTIC FACTOR OF p53 GENE DELECTION DETECTED BY FISH IN MULTIPLE MYELOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION 94
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent 94
ANALISI SEQUENZIALE DELLA TRISOMIA 12 NELLA LEUCEMIA LINFATICA CRONICA 92
ALTE DOSI: QUESTIONI APERTE E SVILUPPI FUTURI 92
Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. 92
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma 92
null 90
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 89
DIABETIC FOOT DISEASE IN A PATIENT WITH MULTIPLE MYELOMA RECEIVING THALIDOMIDE 88
Spontaneous rupture of spleen during peripheral blood stem cell mobilization in a patient with breast cancer 88
Circulating Mitotic Figures In A Patient With Dual Infection By Epstein-Barr Virus And Cytomegalovirus. 85
null 81
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 81
SUCCESSFULL MOBILIZATION OF PERIPHERAL PROGENITOR CELLS WITH PACLITAXEL AND LENOGRASTIM PATIENTS WITH METASTATIC BREAST CANCER 80
Uso di Bortezomib come terapia di prima linea nella leucemia plasmacellulare primaria 79
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence 79
Immunochemotherapy with temozolomide and rituximab for central nervous system lymphomas in an elderly population. 79
Pitfalls of positron emission tomography for assessing relapse in Hodgkin'sdisease: a case report 78
GENE EXPRESSION PROFILING DOES NOT IDENTIFY MOLECULAR SUBGROUP AMONG NODAL PERIPHERAL T-CELL LYMPHOMAS 76
Single-dose pegfilgrastim after chemotherapy is sufficient for mobilisation of peripheral blood stem cells in patients with multiple myeloma 75
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate. 75
Sequential treatment with alemtuzumab and rituximab can induce long-term responses in splenic marginal zone lymphoma 75
null 75
Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors 75
ERYTHROPOIETIN IN COMBINATION WITH LENOGRASTIM AFTER CYCLOPHOSPHAMIDE IMPROVES PERIPHERAL BLOOD PROGENITOR CELL YIELD IN MULTIPLE MYELOMA PATIENT 74
ERYTHROPOIETIN IN CONJUNCTION WITH H.D. VP16 AND LENOGRASTIM ENABLE PBPC COLLECTION IN MULTIPLE MYELOMA PATIENTS WHO FAILED CTX INDUCED MOBILIZATION 74
IMPIEGO DELLA AMIFOSTINE+HD VP16+G-CSF NEI PAZIENTI CON MIELOMA MULTIPLO CHE NON MOBILIZZANO DOPO CTX+G-CSF 73
MOBILIZZAZIONE DI CELLULE NEOPLASTICHE IN CORSO DI TERAPIA AD ALTE DOSI NEL CARCINOMA DELLLA MAMMELLA. NOSTRA ESPERIENZA. 73
PIK3CA mutations in breast cancer: A potential predictive marker 73
Preliminary results of a phase II study of amifostine for patients with myelodisplastic syndrome 72
Risk of second malignant neoplasm among patients with lymphoma 72
null 72
Single-dose of pegfilgrastim after chemotherapy is sufficient for mobilization of peripheral blood stem cells in patients with multiple myeloma 71
Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab 71
RESPONSE TO IMATINIB IN CHRONIC MYELOPROLIFERATIVE DISEASES WITH ACTIVATION OF THE PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR (PDGF betaR) 71
IMPIEGO DELLA AMIFOSTINA NELLE PROCEDURE DI MOBILIZZAZIONE. NOSTRA ESPERIENZA 71
Salvage therapy for primary central nervous system lymphoma with Y-90-Ibritumomab and Temozolomide 71
Totale 10.553
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.456
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.456
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021378 0 0 0 0 0 96 8 84 16 89 57 28
2021/2022848 6 139 18 17 25 3 58 27 5 160 154 236
2022/20232.164 173 209 102 170 187 205 23 136 855 9 71 24
2023/2024445 38 88 29 57 28 83 14 34 3 22 3 46
2024/20252.370 28 34 31 145 106 71 33 597 606 156 183 380
2025/20263.489 325 390 478 362 535 1.399 0 0 0 0 0 0
Totale 11.907